This site is for US health care professionals only.
Novartis Oncology Service Request Form
The Novartis Oncology Service Request Form is used to assess patient eligibility for Novartis Oncology programs including financial assistance and free trial offers. To complete a single request, both the health care professional (HCP) and patient must submit information via 2 separate forms. Fill out the HCP form and alert your patient to complete the patient form. The HCP and patient submissions will be matched after both parts are submitted.
If you would like further information on this process, please call us at 1-800-282-7630, or visit
AFINITOR DISPERZ® (everolimus tablets for oral suspension)
AFINITOR® (everolimus) tablets
EXJADE® (deferasirox) tablets for oral suspension
GLEEVEC® (imatinib mesylate) tablets
JADENU® (deferasirox) tablets
JADENU® Sprinkle (deferasirox) granules for oral use
KISQALI® (ribociclib) tablets
KISQALI® (ribociclib) tablets FEMARA® (letrozole) tablets Co-Pack
MEKINIST® (trametinib) tablets
PIQRAY® (alpelisib) tablets
PROMACTA® (eltrombopag) tablets
RYDAPT® (midostaurin) capsules
SANDOSTATIN® LAR DEPOT (octreotide acetate for injectable suspension)
SIGNIFOR® (pasireotide) injection
SIGNIFOR® LAR (pasireotide) for injectable suspension
TAFINLAR® (dabrafenib) capsules
TAFINLAR® (dabrafenib) capsules and MEKINIST® (trametinib) tablets
TASIGNA® (nilotinib) capsules
TYKERB® (lapatinib) tablets
VOTRIENT® (pazopanib) tablets
ZYKADIA® (ceritinib) capsules
Other Novartis Oncology Product
Please call or send an email to your patient with instructions and a link to complete his or her part of the patient Novartis Oncology Service Request Form:
Once the patient has completed and submitted his/her form, it will be matched with your Service Request Form and your order will be processed.
Please expect a call and/or fax from Patient Assistance Now Oncology (PANO) within
24 to 48 hours
NOTE: If your state requires, please submit a state-approved prescription with this completed form.
NOTE: Depending on selected programs, additional prescriptions may be required.
Use of website is governed by the
Copyright © 2019
Novartis Pharmaceuticals Corporation
. All rights reserved.